Table 2.
Comparison of the baseline characteristics of SCLC between patients in the IPF and no-IPF groups.
| Characteristics | IPF | No-IPF | P-value |
|---|---|---|---|
| Number of patients | 18 | 72 | |
| Age, years | 70.4 ± 7.6 | 70.0 ± 6.9 | 0.828 |
| Male | 17 (94.4) | 68 (94.4) | > 0.999 |
| Ever-smoker | 16 (100.0) | 57 (95.0) | 0.487 |
| BMI, kg/m2 | 23.9 ± 2.7 | 23.3 ± 3.4 | 0.543 |
| Cough | 16 (88.9) | 39 (57.4) | 0.013 |
| Dyspnea | 13 (76.5) | 30 (45.5) | 0.022 |
| PFT | |||
| FVC, % predicted | 65.3 ± 13.4 | 73.3 ± 13.6 | 0.055 |
| DLco, % predicted | 46.1 ± 13.4 | 65.7 ± 18.1 | < 0.001 |
| TLC, % predicted | 64.3 ± 13.5 | 82.5 ± 17.0 | 0.006 |
| Stage | > 0.999 | ||
| Limited | 3 (16.7) | 12 (16.7) | |
| Extensive | 15 (83.3) | 60 (83.3) | |
| Location of cancer (lobe) | 0.111 | ||
| Upper or middle | 6 (33.3) | 36 (54.5) | |
| Lower | 12 (66.7) | 30 (45.5) | |
Data are presented as mean ± SD or number (%), unless otherwise indicated.
SCLC small cell lung cancer, IPF idiopathic pulmonary fibrosis, BMI body mass index, PFT pulmonary function test, FVC forced vital capacity, DLco diffusing capacity for carbon monoxide, TLC total lung capacity.